Date: 2011-02-15
Type of information: Development agreement
Compound: companion diagnostic test to identify FLT3 positive acute myeloid leukemia (AML) patients for specific use in connection with midostaurin (PKC412)
Company: Invivoscribe Technologies (USA) Novartis (Switzerland)
Therapeutic area: Cancer Oncology
Type agreement: development
commercialisation
Action mechanism:
Disease: FLT3 positive acute myeloid leukemia
Details: Invivoscribe Technologies has entered into a collaboration agreement with Novartis to develop and commercialize a companion diagnostic test. The test aims to identify FLT3 positive acute myeloid leukemia (AML) patients for specific use in connection with the Novartis development compound, midostaurin (PKC412).
Midostaurin, a targeted small molecule inhibitor of FLT3 tyrosine kinase, is currently in Phase III clinical development for newly diagnosed patients with FLT3 mutated AML who are receiving midostaurin or a placebo in combination with chemotherapy (NCT00651261). FLT3 is mutated in approximately one-third of all AML patients and FLT3 mutations are associated with poor prognosis.
Invivoscribe and LabPMM will develop, manufacture and work with the Novartis Molecular Diagnostics (MDx) unit to obtain regulatory approval for the companion diagnostic. Invivoscribe and Novartis MDx will then work together to make the companion diagnostic for treatment of AML available throughout the world.
Financial terms:
Latest news:
